Engflag

Finallerg 10mg

Quick links to important sections

Finallerg 10mg

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finallerg 10mg

Property Description
Active ingredient Cetirizine Dihydrochloride
Form Oral Preparation (typically film-coated tablet)
Pharmacological class Second-generation Antihistamine
General Purpose Relief from symptoms of allergic reactions
Origin Synthetic (metabolite of hydroxyzine)

What Type of Medicine Is Finallerg 10mg?

Finallerg 10mg is a synthetic pharmaceutical agent containing the active ingredient Cetirizine Dihydrochloride. It is categorized as a second-generation antihistamine, placing it within the pharmacological class of Selective Peripheral H₁-receptor Antagonists. This classification defines the drug’s core action: blocking the effects of histamine, the primary chemical mediator released during an allergic response.

The second-generation classification exhibits peripheral selectivity. This compound is differentiated by its reduced ability to cross the blood-brain barrier compared to older antihistamines. This key characteristic ensures that Finallerg 10mg delivers effective anti-allergic action while mitigating the significant sedative impact associated with first-generation agents.

Composition, Origin, and Formulation

The formulation contains Cetirizine Dihydrochloride as its sole active ingredient. Chemically, Cetirizine is a synthetic compound that originated as an active metabolite of the drug hydroxyzine. Finallerg 10mg is typically presented as a single-ingredient oral preparation, commonly a film-coated tablet designed for the oral route of administration.

This specific 10mg strength is standardized for symptomatic relief in patient populations requiring systemic management of allergy symptoms. The tablet form ensures stability and consistent systemic absorption.

General Purpose of This Antihistamine Class

The general purpose of Finallerg 10mg is to deliver focused anti-allergic action by preventing the binding of the natural chemical histamine to peripheral H₁ receptors.

By acting as an antagonist, the drug interrupts the mechanism that causes many of the physical discomforts related to allergic responses. This mechanism is the basis for its utility in providing general symptomatic relief by controlling the body's overreaction to allergens, relying on its high peripheral selectivity for targeted relief.

What side effects are possible with Finallerg 10mg?

Finallerg 10mg: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for cetirizine hydrochloride (Finallerg 10mg), as established in government regulatory documents (e.g., FDA, EMA, Health Canada).

Frequency-Classified Adverse Reactions

The most commonly reported effects are generally related to the Central Nervous System (CNS) and digestive system. Frequencies are determined by regulatory authorities:

Frequency Adverse Reaction (Examples)
Common (ge 1/100 to <1/10) Drowsiness (Somnolence), Fatigue, Dry Mouth, Headache, Dizziness
Uncommon (ge 1/1,000 to <1/100) Agitation, Paraesthesia, Diarrhoea, Rash, Pruritus (itching)
Rare (ge 1/10,000 to <1/1,000) Tachycardia (fast heartbeat), Hypersensitivity, Aggression, Convulsions, Abnormal Liver Function, Urticaria
Very Rare (<1/10,000) Anaphylactic Shock, Thrombocytopenia, Syncope, Tremor, Urinary Retention, Angioedema
Not Known Increased Appetite, Pruritus after discontinuation (withdrawal pruritus)

Serious Adverse Reactions

Although rare, serious adverse reactions documented in the official safety profile include Anaphylactic Shock, Angioneurotic Oedema (severe localized swelling), Convulsions, and clinically significant Abnormal Liver Function (elevation of hepatic enzymes with bilirubin).

Safety Restrictions and Limitations

The use of cetirizine is Contraindicated in patients with severe renal impairment (Creatinine Clearance < 10 ml/min) and in those with known hypersensitivity to the drug, any excipients, or hydroxyzine. Caution is necessary for all patients when driving or operating machinery due to the risk of drowsiness. The concomitant use of alcohol or other CNS depressants should be avoided as it may further reduce alertness.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose occurs from ingesting an amount of Finallerg that is greater than the recommended 10 mg dose within a 24-hour period. All authoritative regulatory information underscores that any suspected overdose requires immediate action, even if the individual appears well.

Documented Overdose Presentations

Official regulatory sources note that the primary physiological systems affected in an overdose situation relate to the Central Nervous System (CNS). The documented clinical manifestations associated with ingesting an excessive amount may include:

  • Drowsiness: A feeling of sleepiness or reduced alertness.
  • Excitation: A state of restlessness or overactivity, which may be observed especially in children following an overdose.

Required Emergency Response

If an overdose is suspected or confirmed, the regulatory mandate is to seek emergency medical help or contact a Poison Control Center right away.

The time-critical nature of the response is emphasized because the full extent of the overdose effects may not be immediately apparent. Therefore, do not wait for the onset of severe symptoms; the decisive action is to contact emergency services for guidance immediately following the suspected ingestion.

Therapeutic Uses of Finallerg 10mg

What Finallerg 10mg Treats: Main Uses and Benefits

Finallerg 10mg (Cetirizine Dihydrochloride) is commonly used across specific therapeutic domains, providing supportive relief that may assist patients with managing the symptomatic discomfort of allergic episodes. The primary therapeutic domains where this medication is used involve addressing symptoms related to seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and the recurrent manifestations of chronic urticaria (hives).

Relief for Respiratory and Ocular Allergies

This domain covers the management of symptoms related to upper respiratory and nasal discomfort associated with airborne allergens. Finallerg 10mg is applied in situations where symptoms such as recurrent sneezing, excessive runny nose (rhinorrhea), and persistent itching of the nose and eyes create noticeable interference with daily stability. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

Managing Skin Symptoms and Chronic Discomfort

Finallerg 10mg is considered relevant in conditions marked by increased discomfort due to skin symptoms, primarily chronic urticaria and generalized itching (pruritus). It helps address symptom clusters that may become intense or disruptive and may assist with managing the discomfort of these recurrent manifestations. This supportive therapeutic benefit provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Itching and Sneezing The medication is commonly used to help with symptom clusters that involve symptoms related to inflammatory or irritative states, such as skin itching (pruritus) and respiratory manifestations like sneezing and rhinorrhea.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Finallerg 10mg (Cetirizine)

This eligibility profile summarizes the population restrictions and contraindications for Finallerg 10mg, based strictly on official regulatory labeling.

Contraindicated Populations

Use of Finallerg 10mg is strictly contraindicated (must not be used) in patients who have a known hypersensitivity or allergy to the active substance cetirizine hydrochloride, any of its inactive ingredients, or to its parent compound, hydroxyzine. It is also contraindicated for patients with End-Stage Renal Disease (ESRD) requiring dialysis, due to severe impairment of drug clearance.

Conditional and Restricted Use

Certain populations must consult a healthcare professional before use due to required dose adjustments or increased risk:

  • Impaired Organ Function: Patients with kidney disease (renal impairment) require a lower dose, often determined by a physician, as the body's ability to eliminate the drug is decreased. Dose adjustment may also be necessary in cases involving both hepatic (liver) and renal impairment.
  • Age: The 10 mg tablet is generally recommended for adults and children 12 years and older. Use in children under 6 years of age is restricted and requires specific medical guidance, often requiring liquid formulations for accurate dosing.
  • Pregnancy and Lactation: Use in pregnant or breastfeeding women is generally not recommended or should only be used after consultation with a healthcare professional.
  • Specific Conditions: Patients with a history of seizures/epilepsy or a predisposition to urinary retention should use the medicine with caution and seek medical advice first.

What should I know about interactions with other medicines?

Finallerg 10mg (which contains cetirizine) has a generally low risk for significant drug-drug interactions. However, it is essential to be aware of potential interactions, primarily those that can increase the effect of drowsiness. Always inform your healthcare provider about all prescription and over-the-counter medications, herbal products, and supplements you are currently taking.

Increased Drowsiness Risk

The most clinically relevant interactions involve substances that also affect the central nervous system (CNS). Taking Finallerg 10mg with these products can lead to increased sedation, dizziness, or impaired alertness and coordination, a state known as CNS depression. Patients should exercise caution and avoid driving or operating machinery until they know how the combination affects them.

Product Category Examples of Agents
Central Nervous System Depressants Sedatives, tranquilizers, sleeping pills (e.g., zolpidem), and some medications for anxiety, depression, or seizures.
Opioid Pain Relievers Hydrocodone, oxycodone, morphine.
Other Antihistamines Particularly first-generation agents (e.g., diphenhydramine).
Alcohol Should be avoided as it significantly enhances the sedative effects of cetirizine.

Other Potential Interactions

There are minor reports of interaction with theophylline (a medicine for asthma and other breathing problems), which may increase the risk of side effects from cetirizine. Additionally, if you have liver or kidney impairment, your body may clear the medication slower, potentially increasing the amount of cetirizine in your system and elevating the risk of adverse effects. Your doctor may need to adjust your dosage in these cases.

Mechanism of Action

Blocking Histamine at Peripheral H1 Receptors

Finallerg 10mg acts primarily as a highly selective antagonist of the Peripheral Histamine H1 Receptors . This molecular action competitively blocks the binding of histamine, thereby interrupting the signaling cascade that normally increases capillary permeability and stimulates peripheral sensory nerve endings in tissues. The mechanism limits histamine-induced changes in capillary permeability and peripheral sensory nerve activity.

Modulating Inflammatory Cell Migration

Beyond its primary receptor action, the drug engages a secondary, H1-independent mechanism by suppressing the movement (chemotaxis) of key inflammatory cells, specifically eosinophils, and reducing the surface expression of cell adhesion molecules on vascular cells. This mechanism limits the infiltration of immune cells from the bloodstream into the site of the response. This secondary mechanism influences the infiltration kinetics of inflammatory cells associated with the late-phase response.

Mechanism of Peripheral Selectivity

The molecule's structure is defined by its low ability to cross the blood-brain barrier (BBB), partially due to active transport via the P-glycoprotein transporter. This characteristic results in high peripheral selectivity, leading to action focused on receptors outside the central nervous system. The mechanism involves limited access to central H1 receptors, which regulate the sleep-wake cycle.

Dosage and Administration Information

How to Use Finallerg 10mg: Administration Guidelines

The administration of Finallerg 10mg (Cetirizine Dihydrochloride) is standardized around a high-level, once-daily protocol. This protocol ensures consistent systemic delivery for the management of symptoms.

Administration Scope Standardized Instruction
Route of Administration The formulation is intended for oral use. The active ingredient is also approved for the intravenous (IV) route in specific injection forms.
Dosing Schedule (Adults 12) The standard regimen is 10 mg once daily. An initial dose of 5 mg once daily may be used based on symptom severity. The maximum dose is limited to 10 mg in a 24-hour period.
Timing in Relation to Meals The medicine may be taken with or without food, as absorption is not significantly affected by meal consumption.
Preparation Requirements The film-coated tablet should be swallowed whole with a liquid. No dilution or specific preparation is required. The 10 mg tablet is scored and can be divided to obtain a 5 mg dose.
Age-Group Administration Rules Older Adults ( 65 years): A starting dose of 5 mg once daily is generally recommended due to potential age-related changes in drug clearance.
Special Procedural Conditions For patients with renal impairment (CrCL 11–31 mL/min) or hepatic impairment, the dose is reduced to 5 mg once daily.
Missed-Dose Rules If a scheduled dose is forgotten, it should be skipped if it is near the time for the next dose. A double dose must not be taken to compensate.

Resulting Procedural Structure

The use protocol directs continuous, once-daily oral administration, with the specific dose determined by age and organ function.

Step Sequence:

  • Take the prescribed oral dose (typically 10 mg) once daily.
  • Ingest the tablet by swallowing it whole with a liquid.
  • If a dose is missed, omit it and continue with the next scheduled dose.

Connection to the Overall Use Protocol The standardized instructions define the exact route and frequency for administering the medicine, ensuring that the necessary quantity is delivered consistently over time. Dose reduction is indicated for older adults and individuals with impaired kidney or liver function, establishing a consistent rule for administration in these specific patient populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Finallerg 10mg

This overview summarizes the structure and nature of the clinical research conducted on Finallerg 10mg (Cetirizine Dihydrochloride). It describes what types of studies have been performed, what they monitored, and where limitations or research gaps exist, based on information reviewed by regulatory bodies.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Clinical research exploring the use of this medicine for respiratory and ocular allergies has relied primarily on short-term and intermediate-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluated outcomes related to physical discomfort, examining measures like Total Nasal Symptom Scores to assess changes in sneezing, runny nose, and itching. Studies and regulatory reviews examined findings related to conditions characterized by fluctuating or episodic manifestations, exploring the time frame of observed effects. Despite the existing body of RCTs, long-term outcomes and the durability of observed symptom changes over periods exceeding 12 weeks are not extensively characterized in the primary research. Furthermore, comparative evidence is lacking for certain head-to-head pairings against every other available second-generation antihistamine.

Evidence for Use in Chronic Urticaria (Hives)

For studies focused on skin symptoms associated with Chronic Urticaria (hives), the evidence base includes multiple RCTs and systematic reviews. These trials measured outcomes related to systemic or functional imbalance using tools like the Urticaria Activity Score (UAS), which monitors the severity of hives and pruritus (itching). Regulatory evaluation documents described the scope and consistency of the evidence base for this pharmacological class in this condition. While research exists, some trials, particularly those investigating altered dosages for persistent symptoms, reported outcomes based on small sample sizes (Small N). Consequently, there is limited information for long-term outcomes describing sustained symptom outcomes over periods longer than three to six months for this chronic condition.

Research Focus on Special Populations

The clinical evidence base has been evaluated in populations beyond the general adult group, including adolescents (ge 12 years) and children (in studies covering various age ranges starting from ge 6 months). The initial research used to support the evidence base in children often relied on data extrapolated from adult populations. While studies have been conducted in pediatric populations, data for certain groups remain insufficient compared to the adult evidence base. Evidence is limited for older adults with multiple pre-existing health conditions (comorbidities) and for its use in pregnancy-related populations.

What Research Gaps and Uncertainties Remain

The research provides context but not individual predictions. The primary research focused mainly on short- and intermediate-term observation, with most pivotal trials involving defined time intervals typically up to three months. Long-term effects are not fully established beyond these observation windows. Comparative evidence is lacking for many direct comparisons needed to fully assess comparative evidence for Finallerg 10mg against all other available second-generation antihistamines. The results apply only to the populations studied under the specific conditions of the research.

Frequently Asked Questions (FAQ)

Common questions about Finallerg 10mg (FAQ)

Q: What is the difference between Finallerg 10mg and Zyrtec?

Finallerg 10mg contains the active ingredient Cetirizine Hydrochloride. According to regulatory labels and product information, Zyrtec is a common brand name for products also containing this same active ingredient. Official documents often group products by their shared active pharmaceutical ingredient (API), regardless of the brand.

Q: What should I do if I miss a dose of Finallerg 10mg?

Official prescribing information states that if a scheduled dose is forgotten, it should be skipped if it is near the time for the next dose. A double dose must not be taken to compensate for a missed one. The recommended protocol is to continue with the next scheduled administration.

Q: Is Finallerg 10mg an over-the-counter medicine?

The regulatory labels for this active ingredient are often structured as a Drug Facts or OTC (Over-The-Counter) product. This label structure typically corresponds to non-prescription availability for certain strengths and dosage forms.

Q: How quickly does Finallerg 10mg start working?

Studies and official information indicate that the drug generally starts to produce an effect within about one hour after it is taken. This is when the product typically begins to exert its intended effect.

Q: Can Finallerg 10mg be taken with a cold or flu medicine?

Official product information advises caution when taking Finallerg 10mg with any other medications that cause drowsiness or affect the central nervous system (CNS). If a cold or flu medicine contains such ingredients, regulatory documents advise consultation with a healthcare professional due to a potential for increased sedation and impaired alertness.

Q: Is Finallerg 10mg safe to use during pregnancy?

Official label information states that a health professional should be consulted before use in the event of pregnancy. Use during pregnancy is generally not recommended and should only occur after consultation with a qualified healthcare provider to assess individual circumstances.

Q: Is Finallerg 10mg a steroid?

No. Official regulatory documents classify this product as a second-generation antihistamine, which is used to block the effects of the chemical histamine in the body. It does not belong to the class of medicines known as corticosteroids (steroids).

How should Finallerg 10mg be stored and disposed of?

Storage and Protection Requirements

Finallerg 10mg must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from both moisture/humidity and excessive heat above 40 C. Specific formulations, such as liquids, also require protection from light. The medicine must be kept out of the sight and reach of children as a mandatory safety measure.

Container Integrity and Disposal

Product integrity depends on the packaging, and use is prohibited if the protective seal under the cap or the individual blister unit is compromised or broken. Expired or unused Finallerg 10mg must not be discarded with household waste or wastewater. Instead, disposal must follow local pharmaceutical waste regulations or be handled through an established medicine return program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Finallerg 10mg found in:

A-Z Index: